Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo
<p dir="ltr">Despite recent advances in cancer management and therapy, resistance to cytotoxic medications remains a major clinical challenge; hence, combination-based anti-cancer treatment regimens are currently gaining momentum. PTC-209 reduced BMI1 protein expression, while palboc...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , |
| Published: |
2019
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|